FREDERICK, MD, Nov. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that Mundipharma Pty Limited, has added the ActiPatch® Musculoskeletal Pain Therapy medical device to its pain management portfolio by acquiring the distribution rights in South East Asia, for Singapore, Malaysia, Thailand, Indonesia and the Philippines.
“Mundipharma is adding five additional countries to their Australia and New Zealand ActiPatch sales program. We are exceptionally pleased to have Mundipharma’s training programs, clinical credentials, and medical and retail representatives educating physicians and pharmacists on the benefits of ActiPatch® Therapy," said Keith Nalepka, BioElectronics VP Sales and Marketing.
About BioElectronics Corporation:
BioElectronics develops, manufactures, and markets unique drug free, noninvasive neuromodulation pain therapy medical devices. The Company’s technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation for many neurological disorders, and specifically, chronic pain.
The products include ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; and, Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
Mundipharma Pty Limited is a member of a global network of independent associated companies, that are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Mundipharma has over 3 billion dollars in sales worldwide with over 1000 sales reps globally. Established as a leader in the development and provision of medicines for pain, Mundipharma has expanded its portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold.
ActiPatch® is a registered trademark.